London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...
GlaxoSmithKline would consider buying Pfizer’s consumer health business – but only if the price is right, according to the company's chief executive. Emma Walmsley has also been busy shaking ...
The global anti-osteoporosis therapy and fracture healing market is poised for remarkable growth, with projections indicating a rise from USD 14,051.6 million in 2023 to USD 22,427.6 million by 2033, ...
Clovis Oncology, Pfizer, and GlaxoSmithKline have also marketed rival PARP drugs, with the latter two making significant acquisitions – Medivation and Tesaro, respectively – to add the ...
A Bex and T Powles have been involved in the advisory boards of Pfizer, GlaxoSmithKline, Novartis and Bayer. The authors have no other relevant affiliations or financial involvement with any ...
Pfizer, GlaxoSmithKline Intellectual Property Development, Sanofi US Services, Maze Therapeutics, Janssen Biotech, Novartis AG and Boehringer Ingelheim International GmbH. Competing interests None ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback